Lifetime Health Consequences and Cost-effectiveness of Rosiglitazone in Combination with Metformin for the Treatment of Type 2 Diabetes in Spain
- 1 November 2006
- journal article
- review article
- Published by Springer Nature in PharmacoEconomics
- Vol. 24 (S1) , 49-59
Abstract
Objective:To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and...Keywords
This publication has 36 references indexed in Scilit:
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European Heart Journal, 2003
- UKPDS 60Stroke, 2002
- ¿Qué es una tecnología sanitaria eficiente en España?Gaceta Sanitaria, 2002
- Antidiabetic Drugs Present and FutureDrugs, 2000
- Estudio prospectivo a 10 años sobre la incidencia y factores de riesgo de diabetes mellitus tipo 2Medicina Clinica, 2000
- Guías de práctica clínica de la Sociedad Española de Cardiología en prevención cardiovascular y rehabilitación cardíacaRevista Espanola de Cardiologia, 2000
- Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1995
- Hyperglycemie and Microvascular and Macrovascular Disease in DiabetesDiabetes Care, 1995
- An updated coronary risk profile. A statement for health professionals.Circulation, 1991